Sharemaestro company-news research for Belite Bio Inc ADR (BLTE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest BLTE news and sentiment
Belite Bio Inc ADR
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score56Neutral is 50
Early balanced news score
32/100 evidence confidence
96% direct company focus
39 current stories across 14 publishers
Current company news
Early balanced news score
39 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone66/100
→
Published 30-day score56/100
Latest source headline
Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating
marketscreener.com · 04 Sep 2026 19:40
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
39 current stories are mapped specifically to BLTE.
The score uses 14 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.606.
Confidence is 32/100, below the threshold for a firm score.
56/100
News scoreEarly balanced news score
32/100
Confidencethin evidence
96%/100
Company news39 company stories
89/100
Story agreement11/100 difference
News history
Daily score and story count over 30 days
09 Aug24 Aug07 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence12
0.606 after freshness weightingSource breadth100
14 independent publishersCompany relevance96
share tied directly to this companyFreshness44
recency-weighted evidenceAgreement89
how closely stories agreePublisher mix69
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks11 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
04 Sep 202658USD 193.61+27.6%
28 Aug 202651USD 151.72-5.8%
21 Aug 202652USD 161.06-1.1%
14 Aug 202657USD 162.8-0.2%
07 Aug 202651USD 163.05+2.8%
31 Jul 202652USD 158.61+3.4%
24 Jul 202652USD 153.36+2.2%
17 Jul 202650USD 150.08+0.5%
Provisional evidence
News subjects
What is shaping the score
Earnings5417 stories · 44%
Analyst action7110 stories · 26%
Market update509 stories · 23%
Regulatory and legal522 stories · 5%
Balance sheet431 stories · 3%
Source mix
Where the evidence comes from
Investing.com696 stories · 15%
MarketBeat536 stories · 15%
Stock Titan504 stories · 10%
MT Newswires633 stories · 8%
Sahm572 stories · 5%
www.marketscreener.com512 stories · 5%
GlobeNewswire502 stories · 5%
Recurring subjects
Subjects appearing most often
Life Sciences27Earnings23Financial Markets16Clinical Trials11Fda Approval8Biotech6Finance4Pharma3Rare Diseases2Ophthalmology2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral07 Sep 13:33
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 07 Sep 13:33 | 55 | -3 | 30/100 (-9) | 39 (-4) | Provisional |
| 04 Sep 23:59 | 58 | +6 | 39/100 (+10) | 43 (+3) | Measured |
| 03 Sep 23:59 | 52 | +1 | 29/100 (+10) | 40 (0) | Provisional |
| 01 Sep 23:59 | 51 | -1 | 19/100 (-9) | 40 (-4) | Provisional |
| 24 Aug 23:59 | 52 | +0 | 28/100 (-6) | 44 (-5) | Provisional |
| 21 Aug 23:59 | 52 | +0 | 34/100 (-3) | 49 (+1) | Measured |
| 20 Aug 23:59 | 52 | -1 | 37/100 (-1) | 48 (0) | Measured |
| 19 Aug 23:59 | 53 | +0 | 38/100 (-3) | 48 (-1) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#175Tone
marketscreener.comDirect company coverageStored article
Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating
Belite Bio's shares rose after Canaccord Genuity initiated coverage with a Buy rating and a $303 price target. This positive analyst coverage comes amidst other recent news for Belite Bio, including FDA Priority Review for its Stargardt Disease treatment, Tinlarebant. The company is focused on developing therapeutics for retinal degenerative eye diseases and metabolic conditions.
EarningsFinancial MarketsLife Sciences
- Published
- 04 Sep 2026 19:40
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- High · 58/100
- 30-day weight
- 15.8% of the score · 2.7d old
- Duplicates
- 2 consolidated
#257Tone
MT NewswiresDirect company coverageScored from headline
Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says
- Published
- 04 Sep 2026 15:45
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 12.6% of the score · 2.9d old
- Duplicates
- 1 consolidated
#374Tone
Investing.comDirect company coverageStored article
Canaccord initiates Belite Bio stock with buy on Stargardt therapy
Canaccord Genuity initiated coverage on Belite Bio, Inc, ADR (NASDAQ:BLTE) with a buy rating and a $303 price target, citing optimism for its Stargardt disease therapy, Tinlarebant. The drug has shown significant efficacy in trials and has an FDA PDUFA date set for February 12, 2027. Belite Bio also reported a smaller-than-expected loss for Q2 2026 and possesses strong liquidity to fund its U.S. launch.
EarningsFinancial MarketsLife Sciences
- Published
- 04 Sep 2026 11:40
- News subject
- Analyst action
- Why this score
- Analyst upgrade, Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 60/100
- 30-day weight
- 25.4% of the score · 3.1d old
- Duplicates
- 2 consolidated
#469Tone
MT NewswiresDirect company coverageScored from headline
Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target
- Published
- 04 Sep 2026 09:52
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 53/100
- 30-day weight
- 11.8% of the score · 3.2d old
- Duplicates
- 1 consolidated
#564Tone
Investing.comDirect company coverageStored article
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans
H.C. Wainwright has reiterated a Buy rating and a $214 price target for Belite Bio (NASDAQ:BLTE) due to its commercial plans for tinlarebant, a Stargardt disease treatment. The company aims for a March 2027 launch, pending FDA approval, and has outlined a comprehensive commercial strategy with a strong balance sheet to support it. Belite Bio also reported better-than-expected Q2 2026 earnings and received Priority Review for its New Drug Application.
EarningsFinancial MarketsLife Sciences
- Published
- 03 Sep 2026 20:40
- News subject
- Analyst action
- Why this score
- Fda Approval, Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 17.1% of the score · 3.7d old
- Duplicates
- 1 consolidated
#6—Not directional
MarketBeatDirect company coverageStored article
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
Belite Bio has received FDA Priority Review for its new drug application for tinlarebant to treat Stargardt disease type 1, with a PDUFA date set for February 12, 2027. If approved, tinlarebant would be the first treatment for this rare inherited retinal disease, having shown a 35.7% reduction in retinal lesion growth in Phase III trials. The company is actively preparing for commercial launch, including building sales infrastructure, physician education programs, and patient support services, targeting an estimated 53,000 U.S. patients.
FinanceFinancial MarketsLife Sciences
- Published
- 03 Sep 2026 04:01
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.4d old
- Duplicates
- 2 consolidated
#7—Not directional
www.marketscreener.comDirect company coverageStored article
Belite Bio to Participate in Four Upcoming Investor Conferences
Belite Bio, Inc (NASDAQ: BLTE) announced its participation in four upcoming investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, 2026 Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage drug developer focusing on degenerative retinal diseases, will present at these events through fireside chats. Webcasts of these presentations will be available on Belite Bio's investor relations website for 90 days.
Clinical TrialsFinanceHealthcareLife SciencesRetinal Diseases
- Published
- 01 Sep 2026 12:19
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.1d old
- Duplicates
- 4 consolidated
#8—Not directional
Stock TitanDirect company coverageStored article
The FDA set Feb. 12, 2027, for reviewing a Stargardt disease drug
Belite Bio (NASDAQ: BLTE) will host a Virtual Commercial Day on September 2, 2026, to discuss its lead candidate, tinlarebant, for Stargardt disease type 1 (STGD1). The FDA has granted Priority Review for tinlarebant's New Drug Application, with a Prescription Drug User Fee Act (PDUFA) date set for February 12, 2027. The event will feature management, ophthalmology experts, and patients, covering disease overview, unmet needs, treatment landscape, and commercial opportunities if the drug is approved.
EarningsLife Sciences
- Published
- 24 Aug 2026 20:14
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.7d old
- Duplicates
- 1 consolidated
#9—Not directional
markets.businessinsider.comDirect company coverageStored article
Belite Bio to Host Virtual Commercial Day on September 2, 2026
Belite Bio will host a Virtual Commercial Day on September 2, 2026, to discuss Stargardt disease type 1 (STGD1), unmet medical needs, and the commercial opportunity for their drug tinlarebant. The event will feature Belite Bio's management, ophthalmology experts, and individuals with STGD1, following the FDA's recent acceptance and Priority Review designation for tinlarebant's New Drug Application. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027.
Clinical TrialsFda ApprovalFinanceLife SciencesOphthalmology
- Published
- 24 Aug 2026 20:14
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.7d old
- Duplicates
- 3 consolidated
#10—Not directional
Stock TitanDirect company coverageStored article
Belite Bio sets four talks at two medical meetings, including Phase 3 data
Belite Bio (NASDAQ: BLTE) announced that data from its Phase 3 DRAGON study of tinlarebant for Stargardt disease will be presented at two major ophthalmology meetings in August 2026: the SOG Annual Congress in Lausanne and the APVRS Congress in Gold Coast. The presentations will include results from the Phase 3 DRAGON study in adolescent and adult Stargardt disease, new insights, and updates on ABCA4-retinopathy therapy trials in Japan. Tinlarebant is a novel oral therapy aimed at reducing bisretinoid accumulation, which causes retinal disease.
Life Sciences
- Published
- 21 Aug 2026 15:10
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.9d old
- Duplicates
- 1 consolidated
#11—Not directional
GlobeNewswireDirect company coverageStored article
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio, Inc. (NASDAQ: BLTE) will present data from its clinical trials at two upcoming medical conferences: the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress. The presentations will focus on results from the Phase 3 DRAGON study of tinlarebant for adolescent and adult Stargardt Disease. Tinlarebant is an oral therapy designed to reduce vitamin A-based toxins associated with degenerative retinal diseases.
Clinical TrialsLife SciencesNovel TherapeuticsOphthalmologyStargardt Disease
- Published
- 21 Aug 2026 15:10
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.9d old
- Duplicates
- 4 consolidated
#12—Not directional
Quiver QuantitativeDirect company coverageStored article
Belite Bio Announces Tinlarebant Data Presentations at SOG and APVRS Congresses
Belite Bio, Inc. (NASDAQ: BLTE) will present data on its lead therapy, tinlarebant, at two upcoming ophthalmology congresses in Switzerland and Australia. The presentations will focus on the results from the Phase 3 Dragon Study, which evaluated tinlarebant for treating Stargardt disease, an inherited macular dystrophy with no approved treatments. Tinlarebant works by reducing toxic bisretinoid accumulation in the retina and has received several designations to expedite its development.
EarningsLife Sciences
- Published
- 21 Aug 2026 12:12
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.1d old
- Duplicates
- 1 consolidated
#1343Tone
MarketBeatDirect company coverageStored article
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research
Zacks Research has downgraded Belite Bio (NASDAQ:BLTE) from a "strong buy" to a "hold" rating, despite a broader analyst consensus of "moderate buy" with a $205.80 price target. Other analysts maintain bullish outlooks, with price targets ranging from $214 to $270. Insiders have sold shares worth approximately $2.99 million in the past 90 days, while the company continues to develop small-molecule treatments for metabolic and inflammatory diseases.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 20 Aug 2026 11:40
- News subject
- Analyst action
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.3% of the score · 18.1d old
- Duplicates
- 1 consolidated
#14—Not directional
Revelio LabsDirect company coverageStored article
Belite Bio Number of Employees 2026 | Employee Count & Headcount Data
Belite Bio, Inc. (NASDAQ: BLTE) had approximately 50 employees worldwide as of March 2026, representing a 232.6% growth from 2023. The company is actively hiring, with 1 active job posting in 2026, and its workforce is primarily concentrated in North America. The average salary is $151,597, with significant regional variations.
EarningsLife Sciences
- Published
- 19 Aug 2026 09:10
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.2d old
- Duplicates
- 1 consolidated
#1525Tone
dars.gov.etDirect company coverageScored from headline
Belite (BLTE) Earnings Brief: EPS Falls Short of Its Estimate on the Day; Market Read: Shares Finish 0.39% Down in the Current Update - Revenue Report
- Published
- 18 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 2.1% of the score · 20.3d old
- Duplicates
- 1 consolidated
#1638Tone
Investing.comDirect company coverageStored article
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000
Belite Bio CEO Lin Yu-Hsin sold 365 American depositary shares worth over $65,000 on August 12, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock's remarkable 141% return over the past year, shares have recently declined to $166.28 from the transaction price of around $180. Additionally, Belite Bio reported a smaller-than-expected loss for Q2 2026, with an adjusted EPS of -$0.54, exceeding analysts' estimates.
EarningsFinancial MarketsLife Sciences
- Published
- 14 Aug 2026 19:41
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 1.8% of the score · 23.7d old
- Duplicates
- 1 consolidated
#1764Tone
Investing.comDirect company coverageStored article
Benchmark reiterates Belite Bio stock rating on FDA priority review
Benchmark has reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, targeting a PDUFA date of February 12, 2027. Belite Bio plans significant R&D and marketing investments for Tinlarebant's commercial launch in Q1 2027 and is well-capitalized with $280 million in cash and $500 million in investments. This follows a smaller-than-expected Q2 2026 loss and a raised price target from Mizuho.
EarningsFinancial MarketsLife Sciences
- Published
- 14 Aug 2026 19:11
- News subject
- Analyst action
- Why this score
- Analyst upgrade, Buy Rating, Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 0.2% of the score · 23.8d old
- Duplicates
- 2 consolidated
#18—Not directional
Simply Wall St.Direct company coverageStored article
Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run
Belite Bio (BLTE) stock has experienced a significant 431.2% return over the past three years. Despite this impressive performance and regulatory progress for its drug tinlarebant, valuation metrics suggest the stock may be fully priced, trading at a P/B ratio significantly above the industry average. The article suggests that future movements will depend on whether current pricing already accounts for the potential cash generation from its clinical and regulatory milestones.
Clinical TrialsEarningsFda ApprovalFinancial MarketsLife SciencesOvervaluation
- Published
- 14 Aug 2026 15:11
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.9d old
- Duplicates
- 2 consolidated
#1957Tone
SahmDirect company coverageStored article
Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands
Belite Bio (BLTE) is drawing attention after the FDA granted Priority Review to its New Drug Application for tinlarebant, a Stargardt Disease Type 1 treatment. Despite a recent stock pullback following a quarterly loss, the company is considered undervalued by 21.4% according to analyst targets and its fair value estimate of $211.50, driven by its strong cash position and planned R&D and commercialization investments. However, its valuation also carries uncertainties regarding regulatory decisions and expansion data.
BiotechEarningsFda ApprovalFinancial MarketsIntrinsic ValueLife Sciences
- Published
- 14 Aug 2026 12:42
- News subject
- Earnings
- Why this score
- Contract or approval won, Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 1.1% of the score · 24.0d old
- Duplicates
- 4 consolidated
#2069Tone
Investing.com IndiaDirect company coverageScored from headline
Mizuho raises Belite Bio stock price target to $220 on NDA progress
- Published
- 14 Aug 2026 11:30
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 0.1% of the score · 24.1d old
- Duplicates
- 1 consolidated
#2167Tone
www.marketscreener.comDirect company coverageStored article
Mizuho Adjusts Price Target on Belite Bio to $220 From $215, Maintains Outperform Rating
Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal degenerative eye diseases and metabolic conditions.
EarningsFinancial MarketsLife Sciences
- Published
- 14 Aug 2026 11:12
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 40/100
- 30-day weight
- 0.1% of the score · 24.1d old
- Duplicates
- 1 consolidated
#2240Tone
MarketBeatDirect company coverageStored article
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock
Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a target price of $204.40, especially following the FDA's priority review of tinlarebant. However, Belite Bio remains a clinical-stage company reporting ongoing losses, making its valuation dependent on regulatory decisions and clinical success.
EarningsFinancial MarketsLife Sciences
- Published
- 14 Aug 2026 11:12
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 1.2% of the score · 24.1d old
- Duplicates
- 2 consolidated
#2359Tone
GuruFocus.comDirect company coverageScored from headline
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...
This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant with Priority Review, establishing a PDUFA date of February 12, 2027. New secondary endpoint data from the Phase 3 DRAGON study presented at ASRS showed that Tinlarabant halted or slightly decreased QAF values (by ~2%) at month 25, compared to a ~20% increase in the placebo group. The company is initiating
Clinical TrialsEarningsFda ApprovalPharmaRare Diseases
- Published
- 14 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 0.8% of the score · 24.3d old
- Duplicates
- 1 consolidated
#2475Tone
Investing.comDirect company coverageStored article
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips
Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A expenses in preparation for commercialization, Belite Bio maintains a strong cash balance of $780 million to fund future operations and development.
Clinical TrialsEarningsFda ApprovalLife SciencesPharmaRare Diseases
- Published
- 13 Aug 2026 21:40
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 2.2% of the score · 24.7d old
- Duplicates
- 5 consolidated
#2558Tone
SahmDirect company coverageStored article
Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease
Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant would be the first FDA-approved treatment for this rare retinal disease. This development significantly sharpens Belite Bio's investment narrative, moving it from clinical execution to regulatory resolution, with potential revenue projections of $563.2 million and earnings of $318.3 million by 2029.
BIOTECHBiotechCLINICAL-TRIALSClinical TrialsEarningsFDA-APPROVAL
- Published
- 13 Aug 2026 19:41
- News subject
- Earnings
- Why this score
- Contract or approval won, Institutional or insider buying
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 0.8% of the score · 24.7d old
- Duplicates
- 4 consolidated
#26—Not directional
MarketBeatDirect company coverageStored article
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?
Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a "Moderate Buy" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss of $0.54 per share.
EarningsFinancial MarketsLife Sciences
- Published
- 13 Aug 2026 19:40
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.7d old
- Duplicates
- 1 consolidated
#2775Tone
MarketBeatDirect company coverageScored from headline
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS
- Published
- 13 Aug 2026 18:34
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 51/100
- 30-day weight
- 1.1% of the score · 24.8d old
- Duplicates
- 1 consolidated
#28—Not directional
Glance by Eyes On EyecareDirect company coverageStored article
FDA accepts Belite's tinlarebant NDA for Stargardt
Belite Bio, Inc. has received FDA acceptance for its new drug application (NDA) for tinlarebant, an investigational therapy for Stargardt disease type 1 (STGD1). The FDA has granted tinlarebant a priority review, setting the PDUFA target action date for February 12, 2027. If approved, tinlarebant would be the first-ever treatment for STGD1.
Life Sciences
- Published
- 13 Aug 2026 12:42
- News subject
- Market update
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.0d old
- Duplicates
- 1 consolidated
#2930Tone
nasdaq.comDirect company coverageStored article
Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027
(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1), an inherited macular dystrophy condition. Company Profile Belite Bio focuses on degenerative retinal diseases such as Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead can
BiotechClinical TrialsEarningsFda ApprovalFinancial Results
- Published
- 13 Aug 2026 09:42
- News subject
- Earnings
- Why this score
- Loss widened
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 0.7% of the score · 25.2d old
- Duplicates
- 1 consolidated
#3043Tone
Stock TitanDirect company coverageStored article
Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss
Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Despite this regulatory progress, the company reported a wider net loss of $28.4 million for Q2 2026, up from $16.3 million a year prior, due to increased R&D and SG&A expenses as it prepares for tinlarebant's potential launch. Belite Bio maintains strong liquidity with $279.9 million in cash and equivalents and $500.1 million in U.S. treasury investments.
EarningsLife Sciences
- Published
- 13 Aug 2026 09:40
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 2.1% of the score · 25.2d old
- Duplicates
- 2 consolidated
Earlier company news
BLTE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 41 older BLTE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to BLTE, but the headline and available text are not mainly about Belite Bio Inc ADR. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of BLTE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.